Effects of Astaxanthin and Docosahexaenoic-Acid-Acylated Astaxanthin on Alzheimer’s Disease in APP/PS1 Double-Transgenic Mice
- 25 April 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 66 (19) , 4948-4957
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with the characteristics of senile plaques, neuroinflammation, neurofibrillary tangles, and destruction of synapse structure stability. Previous studies have verified the protective effects of astaxanthin (AST). However, whether synthesized docosahexaenoic-acid-acylated AST diesters (AST-DHA) could delay AD pathogenesis remains unclear. In the present study, APP/PSEN1 (APP/PS1) double-transgenic mice were administrated with AST and AST-DHA for 2 months. The results of radial 8-arm maze and Morris water maze tests showed that AST-DHA exerted more significant effects than AST in enhancing learning and memory levels of APP/PS1 mice. Further mechanical studies suggested that AST-DHA was superior to AST in regulating the parameters of oxidative stress, reducing tau hyperphosphorylation, suppressing neuroinflammation, and regulating inflammasome expression and activation in APP/PS1 mice. The findings suggested that AST-DHA attenuated cognitive disorders by reducing pathological features in APP/PS1 mice, suggesting that AST-DHA might be a potential therapeutic agent for AD.Keywords
Funding Information
- Ministry of Education of the People's Republic of China (201762028)
- Shandong Province (U1606403)
- National Natural Science Foundation of China (31330060, U1606403)
This publication has 30 references indexed in Scilit:
- Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3βJournal of Cell Biology, 2015
- Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's diseasePharmacological Research, 2014
- Targeting the β secretase BACE1 for Alzheimer's disease therapyThe Lancet Neurology, 2014
- Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications—A ReviewMarine Drugs, 2014
- The NLRP3 Inflammasome in Alzheimer’s DiseaseMolecular Neurobiology, 2013
- Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloid-induced cytotoxicity in SH-SY5Y cellsBrain Research, 2010
- Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in ratsBehavioural Brain Research, 2008
- Impaired spatial learning in the APPSwe + PSEN1ΔE9 bigenic mouse model of Alzheimer’s diseaseGenes, Brain and Behavior, 2006
- Inflammatory processes in Alzheimer's diseaseProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
- Stability of astaxanthin and canthaxanthin in raw and smoked atlantic salmon (Salmo salar) during frozen storageFood Chemistry, 1998